Synaptogenix Inc (SNPX)

[SF Wolf]

NTRP has updated their Company presentation on their website:

“Paradigm Shift in the Treatment of Alzheimer’s”
February 2017

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/neurotrope%20feb2017%20light.pdf

Below is a summary of the results of the Compassionate Use Patients that were treated with Byrostatin after FDA approval. My expectation is that Neurotrope, after extensive preclinical data, preliminary clinical and Compassionate Use data, will report similar success in their Ph2b study next month. If that is the case it will be transformative for the AD research field and the millions of families living with Alzheimer’s:

Compassionate Use Patients: Overview

Bryostatin Compassionate Use Program: Severe Alzheimer’s Disease

No other reports have ever shown comparable benefits in such severely demented patients – albeit in the absence of age-matched controls.

Patient 1 - 95 y/o ? (JT) – disoriented, intermittent coma, non-verbal

Course: Became alert, attentive; remembered date, place, time; mind active, engaged, watching TV, requested to return to work

Patient 2 - 38 y/o ? (JS) - familial Early-Onset AD due to PSEN1 mutation Non-verbal, drooling, unable to swallow (fed with gastrostomy), attention grossly impaired, spasticity, inability to move

Course: Return of some language and vocalization, swallowing, increased attentiveness to environment & persons, increased range of motion

Patient 3 - 76 y/o white (FC)

Course: MMSE: 2-3 improves to 10 -12; recognizes, vocalizes words ADCS-ADL-sev score: 18 improves to 33; Hallucinations: reduced; Return of complex motor skills – e.g. swimming, billiards
page 14